Search results
1 company and 14 research reports found for "topotarget"
Company results
- Topotarget
Topotarget is a Danish drug development company in the field of oncology. It is focused on developin...
Sector reports
No sector reports have been found.
Research results
-
Topotarget
Termination of coverage
Update | Pharmaceuticals & healthcare | 01/08/2014Edison Investment Research is terminating coverage on TopoTarget (TOPO). Please note you should no longer rely on any previous research or estimates f...
-
Topotarget
FDA accepts filing of Beleodaq
Update | Pharmaceuticals & healthcare | 10/02/2014Topotarget's belinostat, now with the brand name Beleodaq, could be approved on 9 August 2014 (PDUFA date). The FDA has accepted the product filing an...
-
Topotarget
Belinostat filed with FDA
Update | Pharmaceuticals & healthcare | 17/12/2013Topotarget's partner Spectrum Pharmaceuticals has filed belinostat with the FDA. The next landmark is the 74-day letter, which should be received on o...
-
Topotarget
Only a delay
Update | Pharmaceuticals & healthcare | 19/08/2013The filing of belinostat with the FDA has been delayed until Q413, following a pre-NDA meeting. No new data are required; however, Topotarget and its ...
-
Topotarget
Progressing well towards filing
Update | Pharmaceuticals & healthcare | 26/03/2013Topotarget’s key asset belinostat remains on track to be filed with the FDA for the treatment of peripheral T-cell lymphoma (PTCL) in mid-2013 a...
-
Topotarget
The power of BELIEF...
Update | Pharmaceuticals & healthcare | 25/09/2012The BELIEF pivotal study with Topotarget’s belinostat has met its primary endpoint with more than 20% of patients responding to treatment, causi...
-
Topotarget
Time for BELIEF
Outlook | Pharmaceuticals & healthcare | 13/09/2012Data from the BELIEF study on Topotarget’s key asset belinostat due in Q412 could transform the company’s prospects. Positive data could l...
-
Topotarget
Partner committed for now
Update | Pharmaceuticals & healthcare | 12/04/2012Topotarget’s partner, Spectrum Pharmaceuticals, is buying Allos Therapeutics to acquire a potential competitor to Topotarget’s belinostat ...
-
Topotarget
Staying self-sufficient
Update | Pharmaceuticals & healthcare | 09/12/2011Topotarget is undergoing a restructuring so that it is not dependent on a fund-raising before the potential receipt of milestone payments from Spectru...
-
Topotarget
Thoughts on belinostat
Update | Pharmaceuticals & healthcare | 30/08/2011The main potential for belinostat is in solid tumours, although it could gain approval initially in the haematological cancer, peripheral T-cell lymph...
-
Topotarget
Look beyond the setback
Update | Pharmaceuticals & healthcare | 18/03/2011The recent clinical trial failure with belinostat in ovarian cancer does not undermine the investment case despite the share price falling by 20%. Imp...
-
Topotarget
A data rich 2011
Update | Pharmaceuticals & healthcare | 20/01/2011Top-line data from several trials with TopoTarget’s key drug, belinostat, are expected throughout 2011. The most important results are from tri...
-
Topotarget
Betting on belinostat
Outlook | Pharmaceuticals & healthcare | 10/09/2010TopoTarget’s prospects are closely tied to those of its lead drug, belinostat. It is in a pivotal Phase II trial for peripheral T-cell lymphoma...
-
Topotarget
Belinostat deal
QuickView | Pharmaceuticals & healthcare | 09/02/2010TopoTarget’s co-development deal with Spectrum Pharmaceuticals for its HDAC inhibitor belinostat, signed last week, looks to be a transformative ...